BCTXLHIGH SIGNALFINANCIAL10-K

BCTXL executed a massive reverse stock split (reducing outstanding shares from 36.2M to 1.9M) while burning through $26.3M in losses and turning stockholders' equity negative despite raising significant cash.

The 19:1 reverse stock split is a classic distressed biotech move to maintain exchange listing requirements, while the negative stockholders' equity of -$3.8M indicates the company's liabilities now exceed assets. Despite raising cash to $10.5M, the massive $26.3M net loss and going concern warnings signal severe financial distress for this pre-revenue clinical stage company.

Comparing 2025-10-16 vs 2024-10-29View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position shows classic signs of distress despite a cash infusion—cash increased dramatically to $10.5M but was overwhelmed by a staggering $26.3M net loss that pushed stockholders' equity deeply negative to -$3.8M. While R&D expenses declined 21.7% to $21.3M and operating losses improved slightly, the overall burn rate remains unsustainable relative to available cash. The massive reverse stock split combined with negative equity signals urgent capital needs and potential dilution risk for shareholders.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+1117.3%
$862K→$10.5M

Cash position surged 1117.3% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
-449.1%
-$4.8M→-$26.3M

Net income declined 449.1% — review whether driven by operations, interest costs, or non-recurring items.

Current Assets
Balance Sheet
+445.4%
$3.7M→$19.9M

Current assets grew 445.4% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+268.7%
$5.9M→$21.6M

Asset base grew 268.7% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
-136.6%
$10.3M→-$3.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Interest Expense
P&L
-98.8%
$79K→979

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
-46.7%
$7.5M→$4.0M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-21.7%
$27.2M→$21.3M

R&D spending cut 21.7% — could signal cost discipline or concerning reduction in innovation investment.

Accounts Receivable
Balance Sheet
-21.7%
$24K→$19K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+18.4%
-$33.3M→-$27.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2025-10-16
PRIOR — 2024-10-29
ADDED
As of October 15, 2025, 1,883,906 shares of the registrant s common shares, no par value per share, were issued and outstanding.
Changes in legislation and regulations may affect our revenue and profitability There is substantial doubt about our ability to continue as a going concern We are highly dependent on our key personnel; We have an unproven market for our product candidates; We are a pre-revenue clinical stage company; Short sellers may be manipulative and may drive down the market price of our common shares; Future issuance of our common shares could dilute the interests of existing shareholders 3 PART I ITEM BUSINESS BUSINESS Overview of the Company BriaCell Therapeutics Corp.
The Company is currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal 1 Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612 ).
6.7-9.8 months 2 for similar patients reported in the literature in its Phase 2 study of Bria-IMT combination study with retifanlimab.
A completed Bria-IMT Phase 1/2 combination study with retifanlimab (an anti-PD1 antibody manufactured by Incyte) confirmed tolerability and early-stage efficacy (listed on ClinicalTrials.gov as NCT03328026 ).
+7 more — sign up free →
REMOVED
As of October 28, 2024, 36,183,161 shares of the registrant s common shares, no par value per share, were issued and outstanding.
( BriaPro ) may not generate revenue as expected; Clinical trials involve a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results; Future issuance of our common shares could dilute the interests of existing shareholders; and We have a significant number of options and warrants outstanding, and while these options and warrants are outstanding, it may be more difficult to raise additional equity capital.
BUSINESS BUSINESS Overview of the Company BriaCell Therapeutics Corp.
The Company is currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal 1 Phase 3 study in metastatic breast cancer.
6.7-9.8 months 2 for similar patients reported in the literature in its Phase 2 study of Bria-IMT combination study with retifanlimab at the 2023 San Antonio Breast Cancer Symposium.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →